Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch – MESA open-label extension trial of sevasemten in Becker muscular dystrophy continues to enroll nearly all eligible participants – Continuing to advance Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy; on track […]